secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001628280-24-009383
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex posts Q4 net income of $0.1M; FY2023 revenue up 16% to $83.6M
-----------------------------------------------------------------------

- Q4 net sales $21.2M (+1% YoY); Tru Niagen sales $17.6M (+9% YoY).
- Q4 gross margin 61.0% (up 380 bps); net income $0.1M vs loss of $1.4M prior year.
- Full-year net loss improved $11.6M to $4.9M; positive Adjusted EBITDA of $1.9M.
- Cash $27.3M, no debt; positive operating cash flow for fourth consecutive quarter.
- Exceeded FY2023 outlook for gross margin and G&A; expects accelerated growth in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024009383/0001628280-24-009383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024009383/cdxc-20240306.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-009383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer